Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso, Stephen C. Bain, Agostino Consoli et al.
Research Article — Peer-Reviewed Source
Original research published by Marso et al. in New England Journal of Medicine. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
In patients with type 2 diabetes who were at high cardiovascular risk, the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke was significantly lower among patients receiving semaglutide than among those receiving placebo, an outcome that confirmed the noninferiority of semaglutide. (Funded by Novo Nordisk; SUSTAIN-6 ClinicalTrials.gov number, NCT01720446 .).
Full text is available at the publisher.
Read at Publisher| DOI | 10.1056/nejmoa1607141 |
| Journal | New England Journal of Medicine |
| Year | 2016 |
| Authors | Steven P. Marso, Stephen C. Bain, Agostino Consoli, Freddy G. Eliaschewitz, Esteban Jódar, Lawrence A. Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark Warren, Vincent Woo, Oluf H. Hansen, Anders G. Holst, Jonas Pettersson, Tina Vilsbøll |
| License | Open Access — see publisher for license terms |
| Citations | 6,368 |